Genmab A/S Sponsored ADR $GMAB Shares Purchased by Parallel Advisors LLC

Parallel Advisors LLC lifted its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 377.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,720 shares of the company’s stock after purchasing an additional 2,941 shares during the quarter. Parallel Advisors LLC’s holdings in Genmab A/S were worth $77,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in GMAB. Foresight Group Ltd Liability Partnership acquired a new stake in Genmab A/S during the first quarter worth $954,000. Vident Advisory LLC acquired a new stake in Genmab A/S during the first quarter worth $242,000. GAMMA Investing LLC increased its stake in Genmab A/S by 1,465.3% during the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company’s stock worth $656,000 after acquiring an additional 31,343 shares during the last quarter. Fifth Third Bancorp increased its stake in Genmab A/S by 16.6% during the first quarter. Fifth Third Bancorp now owns 42,151 shares of the company’s stock worth $825,000 after acquiring an additional 6,015 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in Genmab A/S by 1.7% during the first quarter. Envestnet Asset Management Inc. now owns 736,326 shares of the company’s stock worth $14,417,000 after acquiring an additional 12,545 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Wall Street Zen raised Genmab A/S from a “hold” rating to a “buy” rating in a research note on Monday, July 28th. Truist Financial raised their target price on Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, July 8th. Guggenheim raised Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price for the company in a research note on Tuesday. Zacks Research cut Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Finally, HC Wainwright lifted their price objective on Genmab A/S from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $40.00.

Genmab A/S Trading Up 2.5%

NASDAQ:GMAB opened at $29.45 on Thursday. The firm has a market cap of $18.89 billion, a PE ratio of 14.80, a price-to-earnings-growth ratio of 1.68 and a beta of 0.93. The stock has a fifty day moving average price of $24.68 and a 200 day moving average price of $21.93. Genmab A/S Sponsored ADR has a 12-month low of $17.24 and a 12-month high of $29.52.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. Equities analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.